LMDXF — LumiraDx Share News
0.000.00%
Last trade - 00:00- $1.64m
- $378.94m
- $254.48m
Brief: LumiraDx Covid-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Brief: FDA Reissues Lumiradx Fast Lab Solutions' Eua For Sars Cov-2 Rna Star Complete Molecular Reagents To Allow High Throughput And Asymptomatic Testing Solutions
Evercore starts with 'outperform' on LumiraDX, Wall Street's highest PT
Brief: LumiraDx Reports Third Quarter 2021 Financial Results
Brief: Lumiradx Reports Use For Its Covid-19 Antigen Test Has Been Expanded To Include Asymptomatic Individuals
LumiraDx jumps on approval for COVID-19 antigen test in India
Brief: Lumiradx Receives Approval For Its Covid-19 Antigen Test For Use In India
Brief: LumiraDx Ltd Announces FDA EUA Submission For Its SARS-COV-2 & Flu A/B Rapid Antigen Test
Brief: LumiraDx Ltd Announces FDA EUA Submission For Its SARS-COV-2 & Flu A/B Rapid Antigen Test
Focus: Rapid COVID-19 tests increasingly scarce, pricey as demand from employers jumps
U.S. STOCKS ON THE MOVE-Outset Medical, Zoom, Applied DNA, gold miners
U.S. STOCKS ON THE MOVE-Carnival Corp, Astrotech, UTime Ltd, Odonate Therapeutics
U.S. STOCKS ON THE MOVE-XL Fleet Corp, TransMedics, GSX Techedu, Homology Medicines
U.S. STOCKS ON THE MOVE-FibroGen, Sos Ltd, Ebang, CA Healthcare
CA Healthcare: Jumps on SPAC deal with diagnostic firm LumiraDx
Brief: CA Healthcare Acquisition Corp Says LumiraDx To List On Nasdaq Via Merger With Co